Takeda Hit With Antitrust Suit Over IBS Drug Amitiza
Takeda Pharmaceutical broke antitrust law when it cut a pay-for-delay deal with Par Pharmaceuticals to keep a generic version of Takeda's anti-constipation drug Amitiza off the market for more than six...To view the full article, register now.
Already a subscriber? Click here to view full article